AMB-702 / Ambrosia Biosciences - LARVOL DELTA

Nonclinical Profile of AMB-702, a Potent and Novel Oral GLP-1 Receptor Agonist (ADA 2026) - "AMB-702 demonstrated exquisite potency, desirable ADME and oral pharmacokinetic properties with robust efficacy in transgenic humanized GLP-1R mice and in the cynomolgus monkey. These data support the potential of AMB-702 as a treatment for obesity and type 2 diabetes. IND-enabling toxicology and safety studies are in progress to support clinical development."

Late-breaking abstract • Diabetes • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Ambrosia Biosciences Announces Preclinical Data Supporting Differentiated Profile of AMB-702, its Novel Small Molecule GLP-1 Receptor Agonist Development Candidate (PRNewswire) - "AMB-702 demonstrated sustained weight loss and reduction in food intake over 7 days of daily dosing in a lean non-human primate (NHP) model. In a head-to-head comparison, AMB-702 achieved placebo-adjusted mean weight loss of 12.6% after 7 days of daily dosing at 2 mg/kg, compared to 5.4% for orforglipron at the same dose and formulation. AMB-702 also demonstrated improved glycemic control and enhanced insulin secretion in an intraperitoneal glucose tolerance test (IPGTT) in a humanized GLP-1 receptor mouse model....'We look forward to advancing AMB-702 into the clinic early next year.'"

New trial • Preclinical • Obesity